FDA Draft Guidance Outlines Safety Framework for Genome Editing Therapies
KEY TAKEAWAYS
- The FDA issued draft guidance on using next-generation sequencing to assess safety of genome editing therapies.
- The Recommendations focus on evaluating off-target effects and genomic integrity in gene therapy development.
The Food and Drug Administration (FDA) has released draft guidance outlining recommended approaches for assessing the safety of genome editing technologies in human gene therapy products. Announced April 14, 2026, the guidance is intended to standardize how sponsors evaluate potential risks—particularly off-target genomic effects—using next-generation sequencing (NGS) as part of investigational and regulatory submissions.
The draft guidance was issued by the FDA’s Center for Biologics Evaluation and Research, providing detailed recommendations on sample selection, reporting practices, sequencing strategies, and analytical parameters. It applies to both ex vivo gene therapies and in vivo approaches. The guidance is designed to inform nonclinical data packages submitted with investigational new drug (IND) applications and Biologics License Applications (BLAs).
According to the agency, the draft builds on prior guidance issued in 2024 and aligns with a broader FDA initiative aimed at accelerating development of individualized therapies for rare and ultra-rare diseases. The recommendations emphasize comprehensive evaluation of genome integrity, including detection of unintended edits and chromosomal alterations that may have safety implications.
FDA officials highlighted the importance of early engagement between sponsors and regulators during therapy development. Programs such as the Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products (INTERACT) and pre-IND meetings are encouraged to help align study design and safety assessment strategies before formal submissions.
The FDA is accepting public comments on the draft guidance for 90 days before issuing a final version.
Source
U.S. Food and Drug Administration. FDA issues draft guidance on genome editing safety standards to advance gene therapy development. FDA News Release. Published Apil 14, 2026. Accessed April 28, 2026. https://www.fda.gov/news-events/press-announcements/fda-issues-draft-guidance-genome-editing-safety-standards-advance-gene-therapy-development?utm_medium=email&utm_source=govdelivery